2022
DOI: 10.1155/2022/5211329
|View full text |Cite
|
Sign up to set email alerts
|

Integrative Bioinformatics Analysis Reveals That miR-524-5p/MEF2C Regulates Bone Metastasis in Prostate Cancer and Breast Cancer

Abstract: Bone metastases are highly prevalent in patients with advanced prostate cancer and breast cancer and have a serious impact on the survival time and quality of life of these patients. It has been reported that microRNAs (miRNAs) are expressed abnormally in different types of cancer and metastases. However, it remains unknown whether the underlying miRNAs are associated with prostate and breast cancer bone metastasis. Differentially expressed miRNAs (DE-miRNAs) and their potential targets in the metastatic proce… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 47 publications
0
2
0
Order By: Relevance
“…Likewise, previous studies have also validated the oncogenic role of MEF2C in cancers, such as pancreatic cancer, 47 hepatic cancer, 45 and breast cancer. 48 In addition, we detected that MEF2C enhanced the transcription of JAGGED1 in gliomas, contributing to the up-regulation of JAGGED1 expression. This finding was congruent with a previous report.…”
Section: Discussionmentioning
confidence: 74%
“…Likewise, previous studies have also validated the oncogenic role of MEF2C in cancers, such as pancreatic cancer, 47 hepatic cancer, 45 and breast cancer. 48 In addition, we detected that MEF2C enhanced the transcription of JAGGED1 in gliomas, contributing to the up-regulation of JAGGED1 expression. This finding was congruent with a previous report.…”
Section: Discussionmentioning
confidence: 74%
“…In MDDC, transcription factor MEF2C accounts for the largest proportion and has the strongest specificity in MDDC_TXNIP, which plays an important role in immune-related pathophysiological state. KLF3 mainly exists in the cell subtypes of terminal differentiation and participates in tumor progression [ 55 ]. We speculate that the therapeutic effect of some immunotherapeutic drugs on patients with lymph node metastasis is limited, which may be closely related to the immune microenvironment of metastatic lymph nodes, specifically related to the suppression of immune cells.…”
Section: Discussionmentioning
confidence: 99%